Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension

Journal of Korean Medical Science

Volumn 29, Issue 7, 2014, Pages 973-979

  Ryoo, Jae Hong ^a,b   Ham, Woo Taek ^c   Choi, Joong Myung ^a   Kang, Min A ^a   An, So Hee ^a   Lee, Jong Keun ^a   Shin, Ho Cheol ^d   Park, Sung Keun ^a,e  

^a Kyung Hee University Hospital   (South Korea)

^b Bucheon Hospital   (South Korea)

^c Sangji University   (South Korea)

^d Sungkyunkwan University School of Medicine   (South Korea)

^e Sungkyunkwan University   (South Korea)

Author keywords

Blood pressure; Non alcoholic fatty liver disease; Prehypertension

Indexed keywords

GLUCOSE BLOOD LEVEL;

ADULT; BLOOD PRESSURE; COHORT ANALYSIS; COMPLICATION; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREHYPERTENSION; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; SMOKING;

ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREHYPERTENSION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SMOKING;

EID: 84922328053     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.7.973     Document Type: Article

References (31)

1. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
3. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-relat-ed mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-12.
4. Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G. Increased prevalence of cardiovascular disease in Type 2 dia-betic patients with non-alcoholic fatty liver disease. Diabet Med 2006; 23: 403-9.
5. Brea A, Mosquera D, Martín E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-con-trol study. Arterioscler Thromb Vasc Biol 2005; 25: 1045-50.
6. Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008; 121: 72-8.
7. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005; 42: 473-80.
8. Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, Bolondi L. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53: 1020-3.
9. Chun H, Park SK, Ryoo JH. Association of serum gamma-glutamyltrans-ferase level and incident prehypertension in Korean men. J Korean Med Sci 2013; 28: 1603-8.
10. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, Jones DW, Kurtz T, Sheps SG, Roccella EJ. Recommendations for blood pres-sure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111: 697-716.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
12. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mul-len KD, Cooper JN, Sheridan MJ. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.
13. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986; 292: 13-5.
14. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, Clark JM. Diagnostic accuracy and reliability of ultrasonography for the detec-tion of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-90.
15. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the meta-bolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As-sociation for the Study of Obesity. Circulation 2009; 120: 1640-5.
16. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009; 203: 581-6.
17. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, Kim YS, Kim CH, Choi SH, Kim W, et al. The relation between non-alcoholic fatty liver dis-ease and the risk of coronary heart disease in Koreans. Am J Gastroen-terol 2009; 104: 1953-60.
18. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and isch-emic heart disease. World J Gastroenterol 2005; 11: 4838-42.
19. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, He-ine RJ, Diamant M. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007; 191: 391-6.
20. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponec-tin expression from human adipose tissue: relation to obesity, insulin re-sistance, and tumor necrosis factor-alpha expression. Diabetes 2003; 52: 1779-85.
21. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-51.
22. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191: 235-40.
23. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
24. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, et al. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol 2005; 100: 850-5.
25. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004; 24: 29-33.
26. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plas-ma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-7.
27. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Di-onysos nutrition and liver study. Hepatology 2005; 42: 44-52.
28. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy nec-essary? Eur J Gastroenterol Hepatol 2003; 15: 539-43.
29. Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liv-er disease among Korean adults. J Gastroenterol Hepatol 2006; 21: 138-43.
30. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Mén-dez-Sánchez N. Prevalence of non alcoholic fatty liver disease in pre-menopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 2010; 9: 402-9.
31. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Casti-glione A, Tiribelli C. The Fatty Liver Index: a simple and accurate pre-dictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33.